SCHEMBL1060795

SCHEMBL1060795

COC(OC)C(=O)c1ccccc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GAA P10253 2/20 0.48
POLB P06746 1/20 0.48
SLC6A3 Q01959 3/20 0.46
SLC6A4 P31645 2/20 0.46
CHRNB2 P17787 2/20 0.46
CHRNB4 P30926 2/20 0.46
CHRNA3 P32297 2/20 0.46
CHRNA4 P43681 2/20 0.46
SCN1A P35498 3/20 0.44
SCN2A Q99250 3/20 0.44
SCN3A Q9NY46 3/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
HNF4A P41235 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28001944 0.85 KAT6A (0.46) BCAT2MEN1KMT2ASMN1; SMN2GAA
SCHEMBL10137801 0.79 BCAT2 (0.57) BCAT2MEN1KMT2ASMN1; SMN2GAA
SCHEMBL21682896 0.76 BCAT2 (0.53) BCAT2MEN1KMT2ASMN1; SMN2GAA
SCHEMBL28821966 0.76 TTR (0.42) MEN1KMT2ASMN1; SMN2GAAHTT
SCHEMBL1775832 0.76 SLC6A3 (0.74) BCAT2MEN1KMT2ASMN1; SMN2GAA
SCHEMBL29639748 0.76 LMNA (0.57) MEN1KMT2ASMN1; SMN2GAAKDM4E
SCHEMBL27718824 0.76 LMNA (0.57) MEN1KMT2ASMN1; SMN2GAAKDM4E
SCHEMBL28534106 0.76 BCAT2 (0.57) BCAT2MEN1KMT2ASMN1; SMN2GAA
SCHEMBL28073219 0.76 BCAT2 (0.57) BCAT2MEN1KMT2ASMN1; SMN2GAA
SCHEMBL29009563 0.75 AKR1C3 (0.55) KMT2ASMN1; SMN2GAAPOLBSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312987-A1 Method, kit and composition for non-destructive in situ repair or relining of deteriorated pipelines with a dual use system APPLIED RESIN S.L. (ES) 2023-10-05 US claimed
EP-4253819-A1 METHOD, KIT AND COMPOSITION FOR NON-DESTRUCTIVE IN SITU REPAIR (RELINING) OF DETERIORATED PIPELINES WITH A DUAL USE SYSTEM Applied Resin S.L. (ES) 2023-10-04 EP claimed
WO-2026105750-A1 HOLDER FOR CELLS, METHOD FOR HOLDING FLOATING CELLS, AND METHOD FOR RECOVERING FLOATING CELLS 日産化学株式会社 2026-05-21 WO disclosed
US-12509608-B2 Biological material adhesion inhibitor NISSAN CHEMICAL CORPORATION (JP) 2025-12-30 US disclosed
US-12427714-B2 Functionalized product fabricated from a resin comprising a functional component and a polymeric resin, and method of making the same NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2025-09-30 US disclosed
US-12360294-B2 3D printed graded refractive index device CARLETON UNIVERSITY (CA) 2025-07-15 US disclosed
WO-2024257789-A1 STRUCTURE FOR CELLS, METHOD FOR MANUFACTURING STRUCTURE FOR CELLS, AND METHOD FOR CULTURING CELLS 日産化学株式会社 2024-12-19 WO disclosed
US-11958971-B2 Photocurable composition, method for producing concave-convex structure, method for forming fine concave-convex pattern, and concave-convex structure MITSUI CHEMICALS, INC. (JP) 2024-04-16 US disclosed
US-11940634-B2 3D printed antenna CARLETON UNIVERSITY (CA) 2024-03-26 US disclosed
CN-110741463-B Method for producing substrate with fine concave-convex pattern, resin composition, and laminate 三井化学株式会社 2024-02-20 CN disclosed
CN-113423745-B Method for producing polymer having compatibility with biological material 日产化学株式会社 2024-01-09 CN disclosed
EP-1873174-A1 PHOTOCURABLE COMPOSITION, ARTICLE WITH FINE PATTERN AND METHOD FOR PRODUCING SAME Asahi Glass Company, Limited (JP) 2008-01-02 EP disclosed
US-7235331-B2 Semi-Interpenetrating polymer network electrolyte, process for producing the same and battery using the same SONY CORPORATION (JP) 2007-06-26 US disclosed
US-6767933-B2 CONTAINING CHARGE TRANSFER COMPOUND BALLINA PTY LTD (AU) 2004-07-27 US disclosed
US-20040044094-A1 Radiation polymerisable compositions having accelerated cure GARNETT JOHN LYNDON (AU) 2004-03-04 US disclosed
US-6573009-B1 Forming three dimensional network films; strength; ion conductivity SONY CORPORATION (JP) 2003-06-03 US disclosed
US-20030073755-A1 Radiation polymerisable compositions BALLINA PTY. LTD. (AU) 2003-04-17 US disclosed
US-20030054257-A1 Electrolyte compound, and electrolyte, process for producing the same and battery using the same NODA KAZUHIRO (JP) 2003-03-20 US disclosed
EP-1024502-A1 COMPOSITION FOR ELECTROLYTE, ELECTROLYTE AND PROCESS FOR PRODUCING THE SAME, AND CELL CONTAINING THE SAME Sony Corporation (JP) 2000-08-02 EP disclosed
US-4738870-A CONTAINING (HYDROXY)PHOSPHINALALKYL ACRYLATE THE DOW CHEMICAL COMPANY (US) 1988-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509608-B2 Biological material adhesion inhibitor ICAM1, EPCAM, VCAM1 BCAT2 1190/4885MEN1 662/4885KMT2A 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.